Back to top
more

Alexion Pharmaceuticals, Inc. (ALXN)

(Delayed Data from NSDQ)

$136.69 USD

136.69
978,618

+3.56 (2.67%)

Updated May 3, 2019 04:00 PM ET

After-Market: $136.70 (%) 5:22 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

NA Value NA Growth NA Momentum NA VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

NA

Industry: NA

Zacks News

Dicerna's (DRNA) A1AT Candidate Gets Orphan Drug Tag in EU

The European Commission confers an orphan drug status on Dicerna's (DRNA) RNAi therapeutic DCR-A1AT for the treatment of congenital alpha-1 antitrypsin (A1AT) deficiency.

Alexion Pharmaceuticals (ALXN) Stock Sinks As Market Gains: What You Should Know

Alexion Pharmaceuticals (ALXN) closed the most recent trading day at $109.82, moving -1.39% from the previous trading session.

3 Reasons Why Alexion (ALXN) Is a Great Growth Stock

Alexion (ALXN) could produce exceptional returns because of its solid growth attributes.

Top Ranked Growth Stocks to Buy for December 16th

Here are four stocks with buy ranks and strong growth characteristics for investors to consider today, December 16th

Kinjel Shah headshot

6 Low Price-to-Book Value Stocks to Buy in December

P/B ratio is emerging as a convenient tool for identifying low-priced stocks with high-growth prospects.

Zacks.com featured highlights include: Quanta Services, Alexion Pharmaceuticals, Jazz Pharmaceuticals and Changyou.com

Zacks.com featured highlights include: Quanta Services, Alexion Pharmaceuticals, Jazz Pharmaceuticals and Changyou.com

Alexion (ALXN) Looks Good: Stock Adds 6% in Session

Alexion (ALXN) saw a big move last session, as its shares jumped more than 6% on the day, amid huge volumes.

Sumit Singh headshot

Create a Standout Portfolio With These 4 Low P/CF Stocks

Investing in stocks based on value analysis is generally considered one of the best practices. In value investing, investors pick stocks that are usually cheap but fundamentally sound.

Zacks.com featured highlights include: Alexion Pharmaceuticals, OpGen, Integer, ReWalk Robotics and Civeo

Zacks.com featured highlights include: Alexion Pharmaceuticals, OpGen, Integer, ReWalk Robotics and Civeo

Urmimala Biswas headshot

5 Discounted PEG Stocks for GARP Investors

Although PEG is categorized under value investing, it follows the principles of both growth and value investing.

Sanghamitra Saha headshot

Adopt Rising P/E Technique With These 5 Top-Ranked Stocks

What bargain hunting? Stocks with a rising P/E can also be worth buying too.

ALXN vs. ILMN: Which Stock Is the Better Value Option?

ALXN vs. ILMN: Which Stock Is the Better Value Option?

Biotech Stock Roundup: CBAY Falls, CCXI Gains, Amgen Acquires Otezla & More

Key highlights of the past week include regulatory and pipeline updates.

The Zacks Analyst Blog Highlights: Vertex, Biogen, BioMarin and Alexion

The Zacks Analyst Blog Highlights: Vertex, Biogen, BioMarin and Alexion

Kinjel Shah headshot

4 Big Drug Stocks Ripe for Takeover After NVS-MDCO Deal

Here are four stocks that boast promising prospects and are most likely to be takeout targets.

Alexion Gets Approval for Label Expansion of Soliris in Japan

Alexion (ALXN) gets Japan Ministry of Health, Labour and Welfare's approval for the label expansion of Soliris.

Alexion (ALXN) Up 3.3% Since Last Earnings Report: Can It Continue?

Alexion (ALXN) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

The Zacks Analyst Blog Highlights: Alexion Pharmaceuticals, Vertex Pharmaceuticals, Incyte and Regeneron Pharmaceuticals

The Zacks Analyst Blog Highlights: Alexion Pharmaceuticals, Vertex Pharmaceuticals, Incyte and Regeneron Pharmaceuticals

Achillion's (ACHN) Danicopan Gets EMA's PRIME Tag for PNH

Achillion's (ACHN) lead pipeline candidate danicopan receives PRIME status from the EMA as a treatment option for PNH in patients, who are not adequately responding to a C5 inhibitor.

4 Big Biotech Stocks Worth Considering Post Q3 Earnings

We highlight a few principal players from the biotech sector, which are likely to witness a winning run in the near term.

ALXN vs. CBM: Which Stock Should Value Investors Buy Now?

ALXN vs. CBM: Which Stock Is the Better Value Option?

Zacks.com featured highlights include: Avinger, Alexion Pharmaceuticals, CyberArk Software, Organovo and Qualys

Zacks.com featured highlights include: Avinger, Alexion Pharmaceuticals, CyberArk Software, Organovo and Qualys

Sanghamitra Saha headshot

What Bargain Hunting? Tap 5 Stocks With Rising P/E

Bet on these top-ranked stocks with rising P/E for outsized gains.

The Zacks Analyst Blog Highlights: AMETEK, Thermo Fisher Scientific, IQVIA, Lowe's Companies and Alexion Pharmaceuticals

The Zacks Analyst Blog Highlights: AMETEK, Thermo Fisher Scientific, IQVIA, Lowe's Companies and Alexion Pharmaceuticals

Alexion (ALXN) Up 10 % YTD on Soliris & Ultomiris Strength

Alexion's (ALXN) stock rises 10% in the year so far as Soliris maintains momentum and Ultomiris gains further traction.